Last Updated: September 28, 2026

CHLOROTRIANISENE - Generic Drug Details

Name: CHLOROTRIANISENE Generic Launch, Drug Patent, and Exclusivity Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for chlorotrianisene and what is the scope of freedom to operate?

Chlorotrianisene is the generic ingredient in two branded drugs marketed by Banner Pharmacaps and Sanofi Aventis Us, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

Summary for CHLOROTRIANISENE

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	4
Drug Master File Entries:	4
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	1
Patent Applications:	3,585
DailyMed Link:	CHLOROTRIANISENE at DailyMed

Recent Clinical Trials for CHLOROTRIANISENE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Federal University of São Paulo	Phase 4
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4

See all CHLOROTRIANISENE clinical trials

Medical Subject Heading (MeSH) Categories for CHLOROTRIANISENE

Antineoplastic Agents, Hormonal
Estrogens, Non-Steroidal

Anatomical Therapeutic Chemical (ATC) Classes for CHLOROTRIANISENE

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for CHLOROTRIANISENE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	TACE	chlorotrianisene	CAPSULE;ORAL	008102-004	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sanofi Aventis Us	TACE	chlorotrianisene	CAPSULE;ORAL	016235-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sanofi Aventis Us	TACE	chlorotrianisene	CAPSULE;ORAL	011444-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.